Kriteriy diagnostiki dosimptomaticheskoy(premorbidnoy) stadii metabolicheskogo sindroma
https://doi.org/10.14341/2071-8713-5084
Abstract
It is well known that metabolic syndrome (MS) substantially increases the risk of the development of cardiovascular disease,
type 2 diabetes and associated mortality. This makes the search of markers of predisposition to MS and predictors of visceral involvement
in people with normal body mass an extremely pressing problem, as it is the basis of early prophylaxis. The aim of the research
was to determine the early (premorbid) markers of MS. Patients: 458 practically healthy young people aged 18-25. Methods: anthropometric
parameters (body mass index, waist circumference), fat component in body composition (FCBC) «BF-306 OMRON»
(Japan), lipid (Triglyceride, Total Cholesterol, LDL-Cholesterol, LHL-Cholesterol) and glucose metabolism parameters (Glucose,
Immunoreactive insulin, C-peptide, Insulin resistance index HOMA-IR). Results. We found a close correlation of FCBC with glucose
(r=0,564-0,427; p=0,01-0,04) and lipid (r=0,547-0,734; p=0,001-0,04) metabolic parameters inherent to MS in young people with
normal body mass, which made it possible to consider FCBC as a marker premorbidity of MS (sensitivity - 100%, specificity - 96%).
Herein we present an algorithm of diagnostic and tactic activities, which can be used in patients of high risk group for development
of MS, including measures of early prophylaxis and preventive therapy.
type 2 diabetes and associated mortality. This makes the search of markers of predisposition to MS and predictors of visceral involvement
in people with normal body mass an extremely pressing problem, as it is the basis of early prophylaxis. The aim of the research
was to determine the early (premorbid) markers of MS. Patients: 458 practically healthy young people aged 18-25. Methods: anthropometric
parameters (body mass index, waist circumference), fat component in body composition (FCBC) «BF-306 OMRON»
(Japan), lipid (Triglyceride, Total Cholesterol, LDL-Cholesterol, LHL-Cholesterol) and glucose metabolism parameters (Glucose,
Immunoreactive insulin, C-peptide, Insulin resistance index HOMA-IR). Results. We found a close correlation of FCBC with glucose
(r=0,564-0,427; p=0,01-0,04) and lipid (r=0,547-0,734; p=0,001-0,04) metabolic parameters inherent to MS in young people with
normal body mass, which made it possible to consider FCBC as a marker premorbidity of MS (sensitivity - 100%, specificity - 96%).
Herein we present an algorithm of diagnostic and tactic activities, which can be used in patients of high risk group for development
of MS, including measures of early prophylaxis and preventive therapy.
References
1. Генетический паспорт - основа индивидуальной и предиктивной медицины / Под ред. В.С.Баранова. СПб.: Изд-во Н.Л., 2009: 528 с.
2. Дедов И.И., Мельниченко Г.А., Бутрова С.А. Жировая ткань как эндокринный орган (обзор литературы) // Ожирение и метаболизм 2006; 1 (6): 6-13.
3. Advanced glycation end-products: a review. R. Singh, A. Barden, T. Mori [et al.] // Diabetologia 2001; 44 (2): 129-146.
4. Altman D.G. Statistics Notes: tests 1: sensitivity and specificity [Электронный ресурс]. D.G. Altman, J.M. Bland // BMJ 1994; 308: 1552. http : // bmj.bmjjournals. com/cgi/content/full/308/6943/1552.
5. Bays H.E. Adiposopathy is a more rational treatment target for metabolic dis-ease than obesity alone // Curr. Atheroscler. 2006; 8: 144-156.
6. Components of the «metabolic syndrome» and incidence of type 2 diabetes. R.L. Hanson, G. Imperatore, P.H. Bennett [et al.] // Diabetes 2002; 51: 3120-3127.
7. Ford E.S. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. E.S. Ford, W.H. Giles, W.H. Dietz // JAMA 2002; 287: 356-359.
8. Ford E.S. Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated With the Metabolic Syndrome // Diabetes Care 2005; 28: 1769-1778.
9. Schmidt M.I., Duncan B.B., Bang H. et al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study // Diabetes Care 2005; 8: 2013-2018.
10. Ingelsson E., Sundstrцm J., Arnlцv J. Insulin resistance and risk of congestive heart failure // JAMA 2005; 20 (294): 334-341.
11. Jolliffe C.J., Janssen I. Development of age-specific adolescent metabolic syndrome criteria that are linked to the Adult Treatment Panel III and Interna-tional Diabetes Federation criteria // J. Am. Coll. Cardiol. 2007; 49: 891-898.
12. Kenchaiah S. Body mass index and vigorous physical activity and the risk of heart failure among men. S. Kenchaiah, H.D. Sesso, J.M. Gaziano // Circulation 2009; 119 (1): 4452.
13. Mancia G., Bombelli M., Corrao G. et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis // Hypertension 2007; 49: 40-47.
14. Eberly L.E., Prineas R., Cohen J.D. et al. Metabolic Syndrome: Risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial // Diabetes Care 2006; 29(1): 123-130.
15. Pietrobelli A., Miller S., Tan Y.X., Nu-ez C., Heymsfield S.B. Phenotyping obese subjects: multi-contact electrode bioimpedance system for practical body composition measurement // Experimental Biology 1999; 3: 68-76.
16. Vasan R.S., Beiser A., Seshadri S. et al. Residual lifetime risk for developing hypertension in middle-aged women and men. The Framingham Heart Study // JAMA 2002; 287: 1003-1010.
Review
For citations:
, Kriteriy diagnostiki dosimptomaticheskoy(premorbidnoy) stadii metabolicheskogo sindroma. Obesity and metabolism. 2010;7(4):24-28. (In Russ.) https://doi.org/10.14341/2071-8713-5084
Views:
501
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
